At NAMS 2025, data shows EB613’s efficacy in young postmenopausal women and those 10 years post-menopause, with potential as a first-in-class oral anabolic treatment to expand access to bone therapy. Entera Bio plans a Phase 3 study following FDA concurrence in July 2025. EB613, an oral PTH(1-34) tablet, demonstrated significant BMD gains at spine, femoral neck, and hip in early postmenopausal women, comparable to later postmenopausal women. These results could revolutionize osteoporosis care, offering an oral anabolic therapy option for fracture prevention. Entera Bio is leading the way in developing oral peptide and protein replacement therapies to address critical unmet medical needs. Entera Bio faces potential challenges in the development and approval process of its product candidates due to various factors such as changes in clinical data interpretation and unexpected disruptions in manufacturing supply chains. The company also relies on third parties for conducting clinical trials and establishing collaborations, while operating as a development stage company with limited history. Entera Bio emphasizes the importance of cautious consideration when relying on forward-looking statements, as outcomes may not always align with expectations. Investors are advised to stay informed and updated on the company’s progress and regulatory compliance. For further information, contact CEO Miranda Toledano at [email protected].

Read more at 1. “Tesla reports record-breaking revenue in Q3 earnings” – CNBC
2. “Apple unveils new iPhone 13 with improved camera features” – Wall Street Journal
3. “Facebook faces antitrust lawsuit over Instagram acquisition” – Reuters
4. “Amazon Prime Day sales surpass $10 billion for the first time” – CBS MarketWatch
5. “Google announces plan to invest $1 billion in renewable energy projects” – Barchart: Entera Bio Presents Positive New Clinical Data from EB613